Comprehensive medication management (CMM) is an important tool to address medication-related morbidity and mortality and reduce health care costs. Medication therapy problems (MTPs) are a significant and costly barrier to improving patient outcomes 1 and with more than half of all Americans taking at least one prescription drug, 2 the need to manage and optimize patients' medications is greater than ever.
As our health care system expands adoption of compensation systems rooted in demonstration of value, it is of utmost importance that pharmacy leaders define and share the value of comprehensive medication management (CMM) services as a key component of team-based care. Clinical pharmacists are best equipped to work collaboratively with other health care providers to improve medication use through the provision of CMM. 4, 5 CMM is the practice of individualized patient care to ensure that each medication a patient is taking is appropriate, effective for the indicated condition, safe for the patient, and able to be taken by the patient as intended. 6, 7 CMM involves the assessment of a patient and development of an individualized care plan to achieve the intended goals of therapy with appropriate follow-up to determine patient outcomes. 6, 7 CMM includes a follow-up evaluation to ensure the patient is meeting their goals for their medication therapy. A requirement of CMM is collaboration among the various members of the health care team. 8 Many primary care clinics offer this service, but it is unclear how closely providers adhere to this definition of CMM.
The literature has discussed the need for a consistent pharmacist patient care process (PPCP). [9] [10] [11] [12] The landmark model proposed by the Joint Commission of Pharmacy Practitioners outlined the recommended PPCP that pharmacists should adhere to in caring for patients. 11 This work was significant because of the endorsement by multiple pharmacy organizations. While there is now general agreement on the elements of the PPCP, no known literature exists examining how closely pharmacists are following the PPCP in practice.
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• Be part of existing primary care medical practices • Represent a diversity of primary care sites (e.g., community-based health centers, safety net clinics, independent primary care clinics) • Have established team-based relationships where clinical pharmacists are authorized by collaborative practice agreements (CPAs) and/or by a documented privileging process to engage in patient encounters • Have an electronic patient registry or a means of identifying patients most in need of CMM • Have read/write access for the clinical pharmacists in the electronic medical records (EMR)
• Have an existing approach to reporting quality measures on a regular basis for practice improvement (e.g., hospitalizations, emergency department visits, clinical care gaps, clinic revenue) • Provide or have the commitment to provide CMM services in accordance with ACCP standards 4 regarding care process and documentation and in the context of team-based care delivery
Aims of this Report
The purpose of this report is to present the findings of Aim 1 where the baseline demographics and the state of CMM within each practice were assessed. Pharmacy practitioners and administrators frequently seek guidance on building CMM practices and understanding of how other sites are delivering CMM services. This is evidenced by the frequent inquiries for this type of information posted on professional listservs such as the American College of Clinical Pharmacy (ACCP) Ambulatory Care PRN, American Society of Health-System Pharmacists (ASHP) Connect, American Pharmacists Association (APhA) ENGAGE, among others. Therefore, this report was created to:
1. Provide a snapshot of CMM practice among a sample of mature primary care clinics currently delivering CMM. 2. Describe the baseline status of CMM service delivery across sites enrolled in the Enhancing Performance in Primary Care Medical Practice through Implementation of Comprehensive Medication Management study. 3. Provide an overview for those practitioners interested in building a CMM practice to guide care delivery and practice management.
METHODS

Survey Design
Two separate surveys were administered: a demographics survey and baseline survey. The demographics survey addressed both pharmacist-level and practice-level demographic questions. The demographics survey consisted of 70 questions; however, response logic limited the total number of questions for individual participants.
The baseline survey addressed seven domains: clinic demographics, pharmacy services, clinic resources for providing CMM, measuring outcomes and quality assurance related to CMM, the pharmacy team, creating a shared vision around CMM, and collaboration within the clinic. These domains were chosen based on the content expertise of the research team, as well as a review of resources previously shared via professional societies and other publicly available reports. 4, [13] [14] [15] [16] [17] [18] The baseline survey was 80 questions.
Both the demographic and baseline survey were reviewed by a survey research consultant at the University of North Carolina who provided feedback and suggestions for improvement on survey structure and items. The baseline survey was pilot tested by four clinical pharmacists practicing in ambulatory care settings May -June 2016. The purpose of the pilot was to gain feedback on the terminology used throughout the survey, ensure that the items were clear and could be answered by participants, as well as to provide any overall feedback on the survey. The survey questions were modified based on pilot tester feedback.
Both the demographic and baseline surveys were built into Qualtrics (Qualtrics, Provo, UT) and administered via email to the lead pharmacist of all participating clinics in August 2016. Participants were asked to complete the surveys within two weeks, and were sent up to three reminders, if necessary.
Two clinics were added to the study in October 2016 and sent the baseline and demographic surveys at that time. In total, 40 clinics completed the CMM demographic and baseline surveys. Results were analyzed descriptively in Microsoft Excel. Table 1 presents relevant demographic information of the lead pharmacists from each of the participating clinics. Most pharmacists had a Doctor of Pharmacy degree, had completed a pharmacy residency, and had obtained at least one board of pharmacy certification. Table 2 illustrates some of the characteristics of the clinics in the study. Most clinics were in Minnesota and were part of a patientcentered medical home (PCMH). While most clinics had CMM programs that had been established for several years, many clinics did not have a pharmacist present five days a week, or one full time equivalent (FTE). Many clinics were teaching clinics and had PharmD students in their practice completing rotations, as well as pharmacy residents which increased the number of pharmacists providing CMM on their team. Table 3 illustrates how CMM visits were conducted in study sites. Two-thirds of sites were using health information technology to prospectively identify CMM patients, but fewer than half of sites had formal criteria that they utilized to identify patients for CMM. Initial CMM visits were typically scheduled for around one hour, while most sites scheduled follow-up visits for a half-hour. Most practices facilitated CMM referrals by including a process for electronic referral in the EMR. There was a lack of standardization of some aspects of the visit. For example, not all sites reported having a systematic process in place for categorizing MTP, or a standard way to document CMM visits. In addition, only half of the study sites had processes in place to assure quality of CMM services. Most sites had a written mission or vision for their CMM program, but not a written business plan or strategic plan. Finally, most sites applied a credentialing process for their pharmacists who provide CMM, but not a privileging process. Table 4 illustrates that there was considerable variation in applying the PPCP. For example, about a quarter of sites reported not always assessing all medications a patient is taking. In addition, many other steps of the patient care process are not always followed, including assessing the indication, effectiveness, safety, and adherence of every medication. Table 5 demonstrates that most pharmacists in the study have developed CPAs for a variety of common conditions. Pharmacists at these sites were utilizing support staff for a variety of CMM-related tasks. Table 6 shows that over half of all pharmacists use support staff for triaging phone calls, scheduling CMM visits, and billing for CMM services. Table 7 describes the members of the care team pharmacists collaborate with and the level of collaboration they feel they have. Table 8 . While most pharmacists bill third party payers for CMM services, only about a third of CMM patient visits actually result in payment. 7.65% ± 13.7 Commercial (i.e., third party payer), mean ± SD 37.6% ± 23 Uninsured/Self-pay, mean ± SD 4.1% ± 6.7 Other, mean ± SD 2% ± 5.9 Payer mix of patients receiving CMM by percentage* Medicare, mean ± SD 40.7% ± 30.0 Medicaid, mean ± SD 18.9% ± 22.8 Dual eligible, mean ± SD 8.4% ± 14.6 Commercial (i.e., third party payer), mean ± SD 27.4% ± 26.0 Uninsured/Self-pay, mean ± SD 2.9% ± 7.4
RESULTS
Pharmacist and Clinic Demographics
Delivery of Pharmacy Services
Other, mean ± SD 1.7% ± 5.3 Source of funding for providing CMM Primary care medical practice 5 (12.5%) The health care organization (e.g., health system, clinically integrated network) 27 (67.5%) School or College of Pharmacy 9 (22.5%) Partnering entity 1 (2.5%) Other 3 (7.5%) Billing third party payers for pharmacist services for pharmacist-provided patient care services 34 (85%) Percent of CMM patients for whom pharmacists receive payment (n=32), mean ± SD 33.83% ± 33.28 Requirement that pharmacists have specific credentials or training beyond their pharmacy degree by payers to whom pharmacists submit claims to provide payment (n = 32) 8 (25%) *Combination of actual and respondent-estimated data Table 9 outlines the various measures that pharmacists indicated they are applying to CMM. 
Measuring CMM Outcomes
(10%)
Change in medication adherence 4 (10%) Medication errors 3 (7.5%) Reduction in emergency room visits 2 (5%) Reduction in number of clinician visits 1 (2.5%) Change in ambulatory care resource utilization for defined groups of patients (e.g., walk-in appointment requests, phone calls to triage) 0 (0%) Our clinical/practice tracks clinical/financial goals, but we do not separate these out for patients receiving our CMM services versus others not receiving our services 14 (35%) I/we are not tracking any measures to describe CMM impact in this clinic.
(5%)
Pharmacists collect data from a variety of sources. While most can use data from the EMR, almost half still rely on manual tracking data, as shown in Table 10 . 
KEY FINDINGS AND IMPLICATIONS
The primary care pharmacists and sites highlighted in this report represent the characteristics of high performing CMM practices in a variety of settings. These data illustrate how CMM is being delivered in primary care and shed light on areas of inconsistency and opportunities for growth, as well as advancements that have been made in terms of CMM delivery, integration, and sustainability. Moving forward, there are a number of key points to consider when delivering CMM.
• Most sites do not have a full-time equivalent pharmacist. o Implications: Part-time presence of a CMM pharmacist can be effective in balancing fiscal restraints and building sustainability. However, it may also limit the degree to which CMM can fully reach a population of need.
• Most sites schedule initial CMM visits for 60 minutes and follow-up visits for 30 minutes.
o Implications: While many visits with primary care providers are scheduled for 20 minutes, to perform a comprehensive assessment and create a care plan for a CMM patient requires significantly more time, both in the initial visit and during subsequent follow-up visits.
• Many clinics do not use formal criteria for identifying patients most in need of CMM.
o Implications: Without standard criteria for identifying patients most in need of CMM, there may be inconsistency in how patients are identified by both pharmacists and other health care providers. Identifying populations that would benefit from CMM may lead to enhanced value of CMM.
• Most practices have facilitated CMM referrals by including a process for electronic referral in the EMR.
o Implications: Electronic referral for CMM patients streamlines the process and fits in with referrals for other services, which may therefore lead to increased uptake of CMM.
• Over half of all study sites use support staff to assist in triaging CMM phone calls, scheduling CMM visits, and billing.
o Implications: Support staff can reduce time spent on administrative tasks, thus freeing up more time for pharmacists to provide CMM. However, there are several additional areas where support staff could be maximized, such as rooming patients and assisting with follow-up.
• Not all sites have adopted a consistent taxonomy for categorizing MTPs or a systematic process for documenting and monitoring resolution of MTPs.
o Implications: Using a standardized approach for categorizing medication therapy problems is a key component of producing fidelity in the care process for CMM. It can help patients, providers, and other pharmacists better understand the PPCP. It can also support consistent delivery of care across pharmacists and help produce consistent outcomes from CMM services.
• Half of the study sites have adopted a process to assure the quality of CMM services delivered by pharmacists.
o Implications: Quality assurance is important to ensure standardization and quality of CMM. The experience of sites that have invested in the development of quality assurance systems for CMM can serve as models for the profession. The profession should also consider ways to support quality assurance in organizations where the number of practitioners committed to CMM service delivery may not effectively allow internally-based quality assurance systems.
• Pharmacists are not always consistently incorporating certain steps of the PPCP in their visits, such as evaluating indication, effectiveness, safety, and adherence of every medication. o Implications: Consistently delivering CMM is of utmost importance. A consistent service needs to be delivered to ensure fidelity, achieve quality outcomes, and demonstrate the value of CMM across settings.
• Many sites are sustainably performing CMM services despite limited or even absent direct revenue from these services.
o Implications: As value-based payment systems grow, there is evidence that the impact of CMM on quality, cost, or other factors is as important, or possibly more important, than ensuring a revenue stream that fully supports CMM services. Those who are seeking to implement CMM should focus on a multi-faceted approach to establishing the business case for CMM services.
• Most pharmacists participating in this study were employed and funded directly by the host organization.
o Implications: While many clinical positions for pharmacists in primary care initially were established through academic partnerships through which the academic institution provided all or most of the salary support, the sites in this study have demonstrated that a value proposition can be established that justifies full funding for CMM services through a health care organization.
Practitioners building CMM practices frequently seek guidance on various aspects of service delivery, such as CPAs, billing, and quality assurance. This report provides an overview for those practitioners interested in building a CMM practice to guide care delivery and practice management, as well as those practitioners already providing CMM who wish to compare their practice to the sites involved in this cohort of mature CMM practices.
